$ASIX

AdvanSix Inc. (ASIX): Results of Operations and Financial Condition

AdvanSix Inc. (ASIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 News Release ADVANSIX ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS 2Q26 Sales of $421 million, up 3% versus prior year 2Q26 Earnings Per Share of $0.12; Adjusted Earnings Per Share of $0.19 2Q26 Cash Flow from Operations of $10 million Parsippany, N.J., August 7,

Original reporting
Published Aug 7, 2026, 10:29 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 10:55 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ASIX
Bearish
high confidence
Mentioned
$ASIX
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ASIXBearishMed
01

Why it matters

Key trading inputs are the magnitude of YoY declines in net income, adjusted EBITDA, and operating cash flow, plus management’s 3Q26 sequential pricing expectation for ammonium sulfate and a 2H26 cash-flow improvement plan tied to capex and working capital.

02

Market read

Traders will likely reprice ASIX around margin and cash-flow deterioration in Plant Nutrients, while also weighing management’s guidance for sequential pricing and 2H26 cash-flow improvement.

03

What to watch

Plant Nutrients volume fell short due to farmer economics, so the market may be over-weighting demand weakness versus potential normalization; also 45Q carbon capture tax credits timing affected prior-year comparability and could distort trend interpretation.

Relevance 7/10Novelty 8/10Timing: pre-market today (8/7) with same-day earnings release and dividend record/payment dates

Background

This is an SEC 8-K filing with Exhibit 99.1 covering AdvanSix’s second quarter 2026 results and forward-looking outlook, including a declared quarterly dividend and conference call details.

Company-level read

Ticker impact

$ASIXBearishHigh confidence
Context

AdvanSix reported 2Q26 sales of $421.3M (+3% YoY) but sharply lower net income and adjusted EBITDA, plus 3Q26 outlook on ammonium sulfate pricing.

Expected impact

Near-term bias likely negative as traders focus on weaker earnings/cash flow and the expectation of 3Q26 sequential pricing decline, despite some offsetting pricing tailwinds.

Evidence & confidence

The filing provides concrete quarterly P&L and cash-flow deltas versus prior year, and it includes specific forward-looking statements for 3Q26 pricing dynamics and 2H26 cash-flow improvement drivers.

Market effects

Plant Nutrients and fertilizer input pricing dynamics (ammonium sulfate, sulfur costs) are highlighted, which can influence sentiment across adjacent ag-chem and industrial chemical names.

Primarily North American fertilizer supply chain exposure via ammonium sulfate fill program and domestic pricing expectations.

Limited direct global read-through, but benzene/propylene and nitrogen pricing references can matter for broader chemical input cost expectations.

Counterpoint

The company emphasizes pricing mechanisms and expects 2H26 cash-flow improvement from reduced capex run-rate and working-capital tailwinds, which could offset near-term earnings weakness.

Key entities

  • AdvanSix Inc.

    Vertically integrated chemistry company reporting 2Q26 financial results and 2026 outlook, including dividend declaration.

  • Erin Kane

    CEO quoted on performance drivers and outlook.

Related articles

$ASIXMed

AdvanSix (ASIX) Offsets Rising Costs With Pricing As Fertilizer Demand Softens

AdvanSix (NYSE:ASIX) reported Q2 sales of $421 million, up about 3% y/y, but adjusted EBITDA fell $24 million to $32 million and adjusted EPS dropped to $0.19. The company said $72 million higher raw material costs were offset by pricing, while fertilizer demand softened, driving unfavorable volume impacts. Guidance includes ammonia volume growth plans for 2026.

$ASIXMed

AdvanSix Inc. Q2 2026 Earnings Call Summary

AdvanSix Inc. reported Q2 2026 sequential earnings improvement, citing raw material costs shifting from a $10 million headwind in Q1 to a $39 million tailwind in Q2, and fully offsetting $72 million in YoY raw material headwinds via pricing. It noted lower plant nutrient volumes, near-record domestic granular ammonium sulfate volumes, and expects sequential EBITDA and cash flow improvement in H2 2026.

$PLBLMed

Polibeli Group Ltd (PLBL): Financial results for H1 2026

Polibeli Group Ltd (PLBL) furnished an SEC Form 6-K — earnings release. Polibeli Group Ltd Announces Unaudited Financial Results for the six months ended June 30, 2026 On September 21, 2026, Polibeli Group Ltd (the “Company”) announced its unaudited financial results for the six months ended June 30, 2026. Business and Strategic Update ● As of the da

$VICRHighAI 8/10

Why is Vicor stock surging today?

Vicor Corporation's stock rose 12.3% after hours after raising its Q3 2026 revenue growth guidance from nearly 10% to over 20%, driven by royalties from its VPD licensing program. Four major companies have licensed the technology, and the CEO noted potential supply disruptions for unlicensed suppliers. The company also recently authorized a $150M share buyback and acquired properties for AI-driven demand. The Nasdaq closed at a record high, led by AI stocks, but broader indices were unchanged.

$OPTULow

Optimum Communications, Inc. (OPTU): Results of Operations and Financial Condition

Optimum Communications, Inc. (OPTU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Item 2.02 Results of Operations and Financial Condition. The information appearing below under Item 4.02 regarding certain previously reported financial information of Optimum Communications, Inc. (the "Company") for the fiscal year ended December 31, 2025, and the fiscal quarter

$ABVXMedAI 8/10

EQS-News: ABIVAX: Abivax Presents Business Updates and First Half 2026 Financial Results

Abivax reported H1 2026 financials with €402.4M in cash and €767.1M from a July offering, extending runway to Q4 2029. Leadership changes include Chris Rabbat as CMO and Tim Kelly as CTO. The company repurchased royalty certificates for €76.5M, reducing debt. R&D expenses rose 38.5% YoY to €107.9M, driven by clinical trial progress and new indications for obefazimod.